SCHEMBL14601904

SCHEMBL14601904

Cc1[nH]c2ccnc(N)c2c1C

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
NOS3 P29474 4/20 0.45
NOS2 P35228 4/20 0.45
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
DHFR P00374 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
RAD52 P43351 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
EGFR P00533 6/20 0.38
ABL1 P00519 1/20 0.38
PRKCA P17252 1/20 0.38
ABL2 P42684 1/20 0.38
NOS1 P29475 1/20 0.36
FYN P06241 1/20 0.36
AHR P35869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL437141 0.77 SMN1; SMN2 (0.51) SMN1; SMN2KDM4EEGFRABL1PRKCA
SCHEMBL30448074 0.72 UTS2R (0.54) ALDH1A1
SCHEMBL10546827 0.72 UTS2R (0.54) ALDH1A1
Hydrochloric Acid SCHEMBL30448693 0.70 UTS2R (0.53) ALDH1A1
SCHEMBL8296004 0.69 NOS2 (0.45) NOS3NOS2KDM4EKMT2ANOS1
SCHEMBL21449726 0.69 NOS2 (0.41) NOS3NOS2KDM4EGAANOS1
SCHEMBL856054 0.68 EGFR (0.44) SMN1; SMN2EGFRABL1PRKCAABL2
SCHEMBL4028988 0.68 AHR (0.47) SMN1; SMN2ALDH1A1EGFRABL1PRKCA
SCHEMBL8295987 0.65 PARP1 (0.44) NOS3NOS2NOS1FYN
SCHEMBL8140613 0.65 FYN (0.53) NOS3NOS2KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US disclosed
US-7157470-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 US disclosed